KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Revenue (2016 - 2026)

Emergent BioSolutions has reported Revenue over the past 16 years, most recently at $156.1 million for Q1 2026.

  • For Q1 2026, Revenue fell 29.75% year-over-year to $156.1 million; the TTM value through Mar 2026 reached $676.8 million, down 11.03%, while the annual FY2025 figure was $742.9 million, 28.81% down from the prior year.
  • Revenue for Q1 2026 was $156.1 million at Emergent BioSolutions, up from $148.7 million in the prior quarter.
  • Over five years, Revenue peaked at $337.9 million in Q2 2023 and troughed at $50.0 million in Q2 2024.
  • A 5-year average of $229.7 million and a median of $239.9 million in 2022 define the central range for Revenue.
  • Biggest five-year swings in Revenue: tumbled 85.2% in 2024 and later skyrocketed 181.8% in 2025.
  • Year by year, Revenue stood at $330.2 million in 2022, then dropped by 16.23% to $276.6 million in 2023, then decreased by 29.61% to $194.7 million in 2024, then fell by 23.63% to $148.7 million in 2025, then grew by 4.98% to $156.1 million in 2026.
  • Business Quant data shows Revenue for EBS at $156.1 million in Q1 2026, $148.7 million in Q4 2025, and $231.1 million in Q3 2025.